WALTHAM, Mass. — August 27, 2025 — Leads & Copy — Dyne Therapeutics Inc. (Nasdaq: DYN) will present at two upcoming investor conferences: the Cantor Global Healthcare Conference 2025 on September 5 at 9:45 a.m. ET in New York and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 9:15 a.m. ET in New York. Live webcasts and replays of the presentations will be available in the Investors & Media section of Dyne’s website.
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, developing therapeutics targeting muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Contacts:
Investors: Mia Tobias, ir@dyne-tx.com, 781-317-0353
Media: Stacy Nartker, snartker@dyne-tx.com, 781-317-1938
Source: Dyne Therapeutics
